It is a semisynthetic antibiotic based on Rifamixin. It has poor oral bioavailability, meaning that very little of the drug will be absorbed into the blood stream when it is taken orally. Rifaximin is used in the treatment of traveler's diarrhea, irritable bowel syndroem and hepatic encephalopathy.
Enteronor: Rifaximin, each tablet contains 200 mg.
Enteronor 400: Rifaximin, each tablet contains 400mg.
The use of specific gastrointestinal non-absorbable antimicrobials, represents a new concept in the treatment of certain gastrointestinal disorders where the bacterial overgrowth can play a role. Uses of this agents are: treatment targeting enteric bacteria and non-systemic and increased tolerability.
Enteronor, Rifaximin, is indicated in: non enteroinvasive bacterial enterocolitis, traveler’s diarrhea, symptomatic treatment of bacterial enterocolitis in patients at risk for associated pathology, immuno-depression or advanced age-resistant; vancomycin-resistant pseudomembranous colitis; acute diverticulitis; post-operative prophylaxis in surgery of the gastrointestinal tract, and as adjuvant therapy in portosystemic or hepatic encephalopathy. Treatment of irritable bowel syndrome (with prevalence of diarrhea or soft feces) and Small Intestinal Bacterial Overgrowth (SIBO).
Enteronor: 20 and 30 coated tablets.
Enteronor 400: 16 and 32 coated tablets.